tirzepatide surpass SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

Tirzepatide is both a GLP-1 and GIP receptor co-agonist

Surgery requires permanent lifestyle changes

Patients must obtain complete medical records that include: Prescription history with specific dosing information and treatment duration Eye examination reports documenting baseline vision status before starting the medication Diagnostic imaging results such as optical coherence tomography (OCT) scans and fundus photography Clinical notes describing when symptoms started, how they progressed, and their severity Laboratory results showing blood glucose control and other relevant metabolic factors Establishing Causation Through Medical Evidence Proving Causation: Medical experts are crucial in supporting claims by providing professional opinions linking Zepbound use to diagnosed vision conditions

If youre experiencing extremely heavy periods, seek medical advice to rule out underlying conditions and prevent complications